Friday – Clinical Track 4A

Full Name(Required)
Enter your first and last names as you would like them to appear on your certificates.
Enter the email you used to register for TOXINS 2026.

Please evaluate the speakers

Topic and Speaker(s)
ExcellentGoodFairPoor
Have we learned anything new about the pathophysiology of migraine and headache?
Rami Burstein, PhD (USA)
Botulinum toxin vs CGRP-targeting monoclonal antibodies: competition or synergy?
Cristina Tassorelli, MD (Italy)
Post-traumatic headache: Is there a role for botulinum toxin?
Lanfranco Pellesi, MD, PhD (Denmark)
Panel Discussion
YesNo
Have we learned anything new about the pathophysiology of migraine and headache?
Rami Burstein, PhD (USA)
Botulinum toxin vs CGRP-targeting monoclonal antibodies: competition or synergy?
Cristina Tassorelli, MD (Italy)
Post-traumatic headache: Is there a role for botulinum toxin?
Lanfranco Pellesi, MD, PhD (Denmark)
Panel Discussion
YesNo
Have we learned anything new about the pathophysiology of migraine and headache?
Rami Burstein, PhD (USA)
Botulinum toxin vs CGRP-targeting monoclonal antibodies: competition or synergy?
Cristina Tassorelli, MD (Italy)
Post-traumatic headache: Is there a role for botulinum toxin?
Lanfranco Pellesi, MD, PhD (Denmark)
Panel Discussion
Strongly disagreeDisagreeNeutralAgreeStrongly agree
Ability to evaluate the latest clinical and scientific research into botulinum neurotoxins
Understanding of the clinical utility of botulinum neurotoxins
Understanding of potential new therapeutic applications of botulinum neurotoxins
Biomedical knowledge of botulinum and other neurotoxins and their application in enhancing therapeutics and improving care

Scam Warning

Due to scam emails being sent, please note that INA will NOT email you to wire money to anyone on the Board of Directors or anyone else from the INA.

Join Our Mailing List

Click here to sign up, and then manage your subscription.